Trial Profile
A phase IIa study of safety and efficacy of NOX-100 for preventing hypotension in patients during hemodialysis sessions
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2016
Price :
$35
*
At a glance
- Drugs NOX 100 (Primary)
- Indications Hypotension
- Focus Therapeutic Use
- Sponsors Medinox
- 30 Dec 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 08 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Jul 2015 as per ClinicalTrials.gov record.
- 08 Apr 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Jul 2015 as per ClinicalTrials.gov record.